KYTX – kyverna therapeutics, inc. (US:NASDAQ)

News

Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $13.00 price target on the stock.
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $16.00 price target on the stock.
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com